Company intelligence / Profile preview
Shanghai Xunyao Biotechnology
Shanghai, Shanghai Shi, Chinastartupportugal.dealroom.co ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Xunyao Biotechnology is developing innovative therapies focused on antibodies, nucleic acids, and cell-based treatments. Its leading programs include a recombinant anti-CD20 humanized monoclonal antibody and a recombinant humanized anti-PEAR1 monoclonal antibody, both in Phase 1 clinical trials for idiopathic pulmonary fibrosis. The company was founded by Professor Junling Liu’s team from Shanghai Jiao Tong University School of Medicine and operates as a mixed ownership entity with strong academic ties. No published late-stage or commercial results as of June 2025.
- Therapeutic areas
- Pulmonology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyNucleic acid therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Strategic partnership with Shanghai Pharmaceuticals Holding Co., Ltd.Academic collaboration with Shanghai Jiao Tong University School of Medicine
Beyond the preview
Go deeper on Shanghai Xunyao Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Xunyao Biotechnology.